Brielle Benyon

The FDA approved subcutaneous Phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase–zzxf – for the treatment of patients with metastatic HER2-positive breast cancer, as well as early-stage HER2-positive breast cancer, as selected by an FDA-approved companion diagnostic test.

The FDA has had a busy couple of weeks, approving new agents to treat a variety of cancers.

The FDA approved tazemetostat to treat relapsed/refractory follicular lymphoma in 2 different indications.

The FDA expanded the approval of gemtuzumab ozogamicin (Mylotarg) to include newly diagnosed pediatric patients (1 month or older) with CD33-positive acute myeloid leukemia (AML).

Due to a lack of time or feeling uncomfortable, many clinicians don’t discuss the sexual issues that cancer survivors face. But leaning on evidenced-based practices may help bridge the conversation.

On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.

It’s difficult to care for patients without that personal touch. One palliative care nurse offers solutions.

Patients participating on phase I clinical trials could benefit from more integration of palliative care.

When patients call their nurses regarding adverse events, they could avoid hospitalizations – and higher costs – according to a recent study.

The PARP inhibitor is the first biomarker-driven therapy for this patient population.

The FDA continues to approve new cancer drugs, with multiple treatment regimens getting the agency’s OK within the last week.

The novel coronavirus (COVID-19) pandemic has drastically affected the way that hepatocellular carcinoma (HCC) is treated, making nurse adaptability crucial in recent months.

While aggressive lymphoma such as mantle cell lymphoma (MCL) typically end in relapse, precision medicine and cellular therapies are improving outcomes for patients, according to Michael Wang, MD.

The FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for the frontline treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK aberrations.

The FDA approved single-agent rucaparib (Rubraca) for the treatment of patients with BRCA1/2-mutant, recurrent, metastatic castrate-resistant prostate cancer.

The FDA approved pomalidomide (Pomalyst) for the treatment of AIDS-related Kaposi sarcoma, that has become resistant to highly active antiretroviral therapy or for patients with Kaposi sarcoma who are HIV-negative.

Oncology Nursing News is launching our very own podcast, and we want to hear from you when it comes to the logo and topics to cover.

Nurses and other qualified healthcare providers could see their student loans forgiven if the new bill is passed.

Palliative care providers must, “lean into patient care in creative ways.”

The recent FDA approval of sacituzumab govitecan for certain patients with triple-negative breast cancer was an exciting one. Here’s what oncology nurses need to know.

The FDA approved selpercatinib for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other thyroid cancers with RET alterations.

Nurses don’t only save lives – they change them. For National Nurses’ Week, survivors and caregivers shared words of appreciation for their oncology nurses.

The FDA granted an accelerated approval to capmatinib for the treatment of adults with metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping (METex14).

Over the last few weeks, the FDA was busy reviewing and approving new cancer treatments.

More services will now be covered by the Centers for Medicare & Medicaid Services.

Many nurses may be seeing patients outside their specialty, as the COVID-19 pandemic continues to cause stress for patients and providers.

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adults with newly diagnosed relapsed/refractory multiple myeloma.

The FDA approved niraparib for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to frontline platinum-based chemotherapy.

Two researchers spoke about the recent FDA approval for this patient population, and what more needs to be done in the space.